IP Library Granted Patent US 11,484,589
Granted Patent B2
US 11,484,589 · App. 16/770,190 · Granted Nov 1, 2022

Vaccine composition for classical swine fever and preparation method thereof

Inventors: Yongjik Lee (Pohang-Si, KR); Dong-Jun An (Anyang-Si, KR); Se Eun Choe (Gwangmyeong-Si, KR); Jae-Young Song (Anyang-Si, KR); In-Soo Cho (Seoul, KR)
Assignees: BIOAPPLICATIONS INC.; REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
A61K39/225A23K50/30A61P31/12C12N7/00C12N15/63A61K2039/542A61K2039/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,484,589
App. No.
16/770,190
Granted
Nov 1, 2022
Kind
B2
Abstract

Provided is a swine fever antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having an autoimmune-enhancing effect by binding the Fc fragment to a swine fever antigen, and a preparation method thereof.

Claims (16)

1. A method for treating classical swine fever, comprising administering to a subject in need thereof a composition comprising a classical swine fever antigen E2 protein fused with a porcine Fc fragment consisting of the amino acid sequence of SEQ ID No. 4 as an active ingredient.

2. The method for treating classical swine fever of claim 1 , wherein the E2 protein comprises the an amino acid sequence of SEQ ID No. 18.

3. The method for treating classical swine fever of claim 1 , wherein the E2 protein is fused with the Fc fragment to have self-adjuvanting effect and increased solubility.

4. A recombinant vector for producing a classical swine fever antigen E2 protein fused with an Fc fragment, comprising a polynucleotide encoding a porcine Fc fragment consisting of the amino acid sequence of SEQ ID No. 4 and a polynucleotide encoding a classical swine fever antigen E2 protein.

5. The recombinant vector of claim 4 , wherein the E2 protein comprises the amino acid sequence of SEQ ID No. 18.

6. The recombinant vector of claim 4 , wherein the recombinant vector comprises a promoter gene operably and sequentially linked to the polynucleotide encoding a classical swine fever antigen E2 protein and the polynucleotide encoding a porcine Fc fragment.

7. The recombinant vector of claim 6 , wherein the promoter is one or more selected from the group consisting of a cauliflower mosaic virus-derived 35S promoter, a cauliflower mosaic virus-derived 19S RNA promoter, an actin protein promoter of a plant, a ubiquitin protein promoter, a cytomegalovirus (CMV) promoter, a simian virus 40 (SV40) promoter, a respiratory syncytial virus (RSV) promoter, a pEMU promoter, an MAS promoter, a histone promoter, a Clp promoter, and an elongation factor-1 alpha (EF-1α) promoter.

8. The recombinant vector of claim 4 , wherein the recombinant vector further comprises a polynucleotide encoding a chaperone binding protein (BiP).

9. The recombinant vector of claim 4 , wherein the recombinant vector further comprises a gene encoding SEQ ID NO: 20.

10. The recombinant vector of claim 4 , wherein the recombinant vector further comprises a 5′ untranslated region (UTR) site gene of M17.

11. The recombinant vector of claim 4 , wherein the recombinant vector increases an expression level of the classical swine fever antigen E2 protein fused with the Fc fragment.

12. A transgenic organism transformed with the recombinant vector of claim 4 .

13. A method for producing a classical swine fever antigen E2 protein fused with an Fc fragment and having an autoimmune-enhancing effect, the method comprising:

(a) culturing a transgenic organism transformed with the recombinant vector of claim 4 ; and

(b) isolating a classical swine fever E2 protein fused with an Fc fragment from the transgenic organism or culture solution and purifying the classical swine fever E2 protein fused with the Fc fragment.

14. The recombinant vector of claim 4 , wherein the E2 protein is fused with the Fc fragment to have self-adjuvanting effect and increased solubility.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE PROPERTY NUMBER 16930208 PREVIOUSLY RECORDED AT REEL: 060390 FRAME: 0122. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jan 11, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 062387/0489 →
CHANGE OF NAME Recorded Jun 20, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 060390/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2020
From: LEE, YONGJIK; AN, DONG-JUN; CHOE, SE EUN; SONG, JAE-YOUNG; CHO, IN-SOO
To: BIOAPPLICATIONS INC.; REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
Reel/Frame 052850/0486 →